Table 1.
Comparison of the general clinical data
| PD patients | Healthy controls | P1 value | Constipation patients | Non-constipation patients | P2 value | |
|---|---|---|---|---|---|---|
| Age (years) | 64.17±8.78 | 60.80±7.33 | 0.210 | 65.14±9.11 | 61.97±7.98 | 0.226 |
| Gender (female) | 9 (31.03%) | 8 (53.33%) | 0.198 | 2 (14.29%) | 15 (50.00%) | 0.044 |
| PD duration (month) | 79.29±46.20 | - | - | 79.29±46.20 | 67.73±42.08 | 0.487 |
| H-Y | 2.32±0.70 | - | - | 2.32±0.70 | 1.90±0.97 | 0.192 |
| UPDRSIII | 22.93±11.69 | - | - | 22.93±11.69 | 14.20±8.91 | 0.031 |
| NMSQ | 14.57±4.20 | - | - | 14.57±4.20 | 8.13±5.15 | 0.001 |
| Wexner | 12.86±4.50 | - | - | 12.86±4.50 | 0.27±0.59 | <0.01 |
| MMSE | 26.79±1.97 | - | - | 26.79±1.97 | 25.80±3.47 | 0.360 |
| PDQ39 score | 51.64±25.02 | - | - | 51.64±25.02 | 26.13±20.06 | 0.005 |
| End of dose deterioration | 9 (64.29%) | - | - | 9 (64.29%) | 2 (13.33%) | 0.008 |
| Dyskinesia | 5 (35.71%) | - | - | 5 (35.71%) | 1 (6.67%) | 0.080 |
| Combined disease | ||||||
| Cerebrovascular disease | 11 (37.93%) | 4 (26.67%) | 0.520 | 5 (35.71%) | 10 (33.33%) | 1.000 |
| Hypertension | 4 (13.79%) | 1 (6.67%) | 0.647 | 2 (14.29%) | 3 (10.00%) | 0.647 |
| Drugs | ||||||
| Levodopa | 14 (100%) | - | - | 14 (100%) | 15 (100%) | 1 |
| Dopamine agonists | 11 (78.57%) | - | - | 11 (78.57%) | 12 (80.00%) | 1 |
| COMT inhibitor | 9 (64.29%) | - | - | 9 (64.29%) | 2 (13.33%) | 0.008 |
| MAOB inhibitor | 10 (71.43%) | - | - | 10 (71.43%) | 3 (20.00%) | 0.009 |
| Antihypertensive drugs | 4 (13.49%) | 1 (6.67%) | 0.647 | 2 (14.29%) | 3 (10.00%) | 0.647 |
| Antiplatelet agent | 11 (37.93%) | 4 (26.67%) | 0.520 | 5 (35.71%) | 10 (33.33%) | 1.000 |
| Statins | 9 (31.03%) | 4 (26.67%) | 1.000 | 5 (35.71%) | 7 (23.33%) | 0.475 |
| Smoking | 9 (31.03%) | 4 (26.67%) | 1.000 | 6 (42.86%) | 7 (23.33%) | 0.288 |